Patient-centered care may sound like a modern concept, but the idea is rooted deeply in the Hippocratic tradition. What has changed over time is how we define it, how we support it, and how we accomplish it in everyday practice. Simply put, patient-centered care is about making sure patients are a part of the care conversation. It requires patient involvement, shared decision-making, and responsiveness to our patients’ individual preferences and values.
In psychiatry, this can be especially challenging. Symptoms such as psychosis, severe mood disturbance, or cognitive difficulties may make it difficult for patients to fully express themselves and their needs. We have to explain diagnosis, treatment options, prognosis, risk, and uncertainty in ways that are grounded in science but are still clear, compassionate, and connected to our patients’ everyday lives. This is harder still when patients and families are already discouraged by delayed or unclear diagnoses, lingering symptoms, side effects, or the feeling that treatment has become a long process of trial and error.
This is where the promise of precision psychiatry comes in. At its best, it offers more information about the person sitting in front of us. By bringing individualized medicine into psychiatry, we not only improve how we diagnose, choose treatments, and talk through options with our patients, but also strengthen shared decision-making, preserve the therapeutic relationship, and support patient autonomy and agency in ways traditional approaches have not always allowed.
Precision psychiatry is especially relevant now because the field is rapidly evolving. Advances in genomics, neuroimaging, digital phenotyping, cognitive assessment, and related tools are giving us new ways to understand patients with greater depth and nuance. Rather than relying solely on traditional assessment methodologies and broad diagnostic categories, precision psychiatry aims to support individualized diagnosis, treatment selection, prevention planning, and preventive interventions through integration of our patients’ unique genetic, neurobiological, psychological, and environmental profiles into our medical decision-making process.
Article Highlights
Precision medicine, generally, is a science-based approach to medical care that considers each patient’s individual genetics, lifestyle, and environment when guiding treatment. Precision psychiatry extends this data-driven personalized medicine model and applies it to mental health with the goal of reducing (or ultimately replacing) what is essentially a trial-and-error approach to treatment with interventions targeted to fit each patient’s individual profile and needs.
Psychiatric disorders are highly heterogeneous, which means that two people can receive the same diagnosis but have very different reasons for developing symptoms, experiences of the illness, and responses to treatment. Depression, anxiety disorders, bipolar disorder, and schizophrenia do not look the same from one person to the next because each condition is shaped by a unique mix of biological, psychological, social, environmental, and personal factors, including trauma exposure. This makes diagnosis and treatment especially challenging in psychiatry.
Traditional psychiatric care often depends on what clinicians observe and what patients are able to report about their symptoms. While this information is important, it can sometimes place patients into broad diagnostic categories that do not always fully capture the complexity of their individual experience, a process that can lead to delayed relief, unnecessary side effects, and outcomes that vary widely from person to person.
Precision psychiatry aims to reduce this variability by matching treatments to the biological and psychological mechanisms underpinning the individual patient’s illness and identifying subgroups with shared biological or clinical traits. Psychosocial factors have a clearer link to mental illness, but biological causes have often been harder to prove, limiting our ability to match patients to effective treatments.
If successful, precision psychiatry could change the practice of clinical psychiatry by providing new opportunities for prevention, early detection, and improved quality of care across the spectrum of severity.
Historically, advances in other clinical fields have outpaced those of psychiatry. Unlike other medical specialties, which can anchor clinical decisions to measurable physiology like hormone levels, viral loads, and imaging findings, psychiatry still lacks validated, scalable biomarkers with enough sensitivity, specificity, reliability, and cost effectiveness to guide routine care for most diagnoses.
Precision medicine is difficult in psychiatry because psychiatric disorders arise from genetic, environmental, and psychosocial factors that do not fit neatly onto biological processes. Our current psychiatric diagnostic systems are based on symptoms and categorical classifications. People with very different underlying disease mechanisms are grouped together under broad diagnoses that rely upon identification of symptom clusters and the traditional evaluation techniques of patient self-report and clinician observation.
Because precision psychiatry tools are derived from these categories, they also inherit the same heterogeneity, which makes it tough to stratify patients into biologically meaningful subgroups.
Complicating matters is the fact that the brain is an incredibly complex organ that is extremely difficult to sample directly in living patients. Psychiatric disorders do not involve localized lesions but rather distributed brain circuits, dynamic processes that respond to experiential and environmental influences.
Further, the brain’s plasticity allows for dynamic adaptation and changes in response to environment, medical comorbidity, sleep deprivation, etc., in ways that impede easy linkage between psychiatric symptoms and identifiable biological mechanisms.
Biomarker discovery has been slow because most potential psychiatric biomarkers face unreliable replication and have failed to predict outcomes at the level of the individual.
The result of these limitations is that psychiatry remains a largely trial-and-error specialty. Interventions that work for some patients may not (and often do not) work for others despite similar outward presentations or symptom clusters. It came late to the game of precision medicine not because there was less need, but because connecting subjective distress, behavior, brain circuitry, molecular biology, and lived environment into tools that are accurate and practical for use in the traditional psychiatric workflow is an exceptionally difficult task.
Psychiatric disorders are measurable medical conditions that affect brain function, emotion, cognition, behavior, and overall health. Their biological underpinnings are supported by extensive research showing meaningful associations with factors that contribute to risk and course:
Through longitudinal and epidemiological psychiatric research, we can track how psychiatric symptoms develop, cluster, and respond to life events over the course of illness. Cross-cultural studies show us that while symptoms of these disorders may vary in expression, the core syndromes appear across cultures.
When compared with healthy controls, neuroimaging data consistently shows that people with conditions like schizophrenia, bipolar disorder, and major depressive disorder (MDD) have structural and functional differences in the brain, and that some treatments can reverse some of these changes.
Genetic research has established that many psychiatric disorders have significant heritability, with genome-wide association studies identifying specific genetic variants associated with risk. Twin and sibling studies show heritability estimates of 35% to 80% for many psychiatric conditions, illustrating that the genetic loading in psychiatric illness is comparable to, and sometimes even greater than, that of many physical health conditions.
In medicine generally, biomarkers can provide measurable information about biological processes, including whether those processes are normal, altered, or associated with disease.
In psychiatry, however, the clinical use of biomarkers remains limited. Although research has greatly improved our understanding of the biological underpinnings of psychiatric disorders, the exact disease mechanisms are still not fully understood. As a result, psychiatry does not yet have objective, universal diagnostic tests. Apart from certain neurodegenerative conditions such as Alzheimer’s disease, no blood test, brain scan, or genetic panel currently exists that can reliably diagnose most psychiatric disorders in routine clinical practice.
Even so, emerging technologies, such as pharmacogenetic testing, digital phenotyping, neuroimaging markers, and other biologically informed approaches, may increasingly complement current methods of psychiatric assessment over time. As the field evolves, clinicians should remain open to new information, avoid becoming overly attached to traditional workflows, and stay current with advances that may improve diagnostic precision, treatment selection, and patient outcomes.
Although many precision psychiatry tools remain experimental, clinicians can already take practical steps to improve patient-centered care and bring greater precision into routine practice. Digital cognitive testing offers one such opportunity because it is accessible, affordable, objective, and easy to integrate into traditional psychiatric workflows.
Digital cognitive testing is a practical entry point for precision psychiatry because it turns cognitive and behavioral science into measurable clinical data that can strengthen diagnosis, guide treatment planning, and support personalized patient monitoring over time.
Digital assessment tools have reduced diagnostic uncertainty in the group practices I manage. By tracking cognitive performance over time, we can diagnose, treat, and monitor progress and outcomes more effectively. This allows the opportunity for more collaboration with our patients. When we show them their measurable precision data and how it, along with other assessment findings and relevant social, emotional, and environmental factors, informs our medical decision-making, we strengthen the therapeutic relationship.
One new patient population we serve includes professional athletes with histories of traumatic brain injury (TBI). Because many cannot tolerate lengthy testing sessions, our neuro team developed a brief, 15-minute Creyos battery covering attention, verbal reasoning, working memory, and deductive reasoning, with an emphasis on frontal and temporal brain functions. When paired with stress profiling, neurology consultation, EEG and brain mapping, and neurologic and psychiatric evaluation, this data helps our team clarify diagnoses, distinguish overlapping conditions such as attention-deficit/hyperactivity disorder (ADHD) and TBI, and identify treatment approaches tailored to each patient rather than relying on standardized interventions.
Treatment options, whether medication, psychotherapy, or neuromodulation such as transcranial magnetic stimulation (TMS), are chosen in collaboration with our patients, integrating precision data with data gleaned from other assessment methods as well as from social, emotional, and environmental factors.
For example, EEG and brain mapping may guide the selection of neurofeedback protocols, while evidence of autonomic dysregulation may indicate a need for biofeedback sessions aimed at calming and regulating the nervous system. Cognitive testing helps us determine whether interventions should target attention, working memory, reasoning, or executive functioning. In this way, the assessment process improves patient-centered care by helping us create individualized treatment plans that meet our patients’ specific neurological, cognitive, and physiological needs.
Another advantage of standardized, easy-to-administer digital cognitive testing is that it supports repeat evaluation over time. In our program, we can easily compare pre- and post-treatment results by readministering the same customized battery of tests at the end of care. Although our work with this group is still in its early stages, follow-up testing has shown improvements in self-regulation, including focus, attention, and impulse control for most patients. Patients also report feeling less stressed and anxious and better able to concentrate.
In short, integrating objective data from digital cognitive assessments has strengthened our assessment process in many ways. By reducing reliance on subjective recall and single-visit symptom reports, improving diagnostic accuracy, and clarifying complex presentations, precision digital tools like Creyos have enhanced our ability to provide personalized, patient-centered care.
Although some precision-oriented tools are already available in select clinical settings, including pharmacogenetic testing, digital cognitive assessment, and EEG-based approaches to predicting treatment response, many scientific, operational, and economic barriers continue to limit their routine use:
Implementation challenges within everyday clinical practice compound these barriers. Many psychiatrists may be cautious about incorporating precision tools into workflows that are already busy, time-sensitive, and shaped by long-standing routines. If these tools seem likely to require extra training, more documentation, or major changes in how care is delivered, clinicians may be less willing to adopt them, even when the tools have the potential to improve patient outcomes.
At the same time, objective biological and behavioral data can help us move beyond broad diagnostic categories so that we can recognize problems earlier, adjust treatment plans sooner, and choose interventions that are more closely matched to our individual patients’ needs.
Importantly, precision psychiatry does not have to replace the human connection at the center of psychiatric care. When used thoughtfully, it strengthens the therapeutic relationship by giving patients and clinicians more information to discuss together. When precision data is explained clearly, respectfully, and collaboratively, our patients feel more seen, heard, and included in decisions about their care.
For precision psychiatry to become truly patient-centered, however, it must be integrated in a way that supports both clinicians and patients. This means developing tools that are easy to use, clinically meaningful, and clearly connected to shared decision-making. Precision psychiatry should be understood as an additional resource, rather than a replacement for clinical judgment or therapeutic rapport, that can help us personalize care while keeping our patients’ lived experiences at the center of treatment.
Looking ahead, the hope is that precision psychiatry will continue to evolve toward the level of clinical integration already seen in other areas of medicine, where biomarkers, risk profiles, and individualized treatment pathways increasingly guide care. If these tools can be developed responsibly and integrated in ways that are practical and equitable, there is every reason to believe it won’t be long until precision psychiatry transforms mental health treatment from a reactive model into one that is predictive, preventive, and always patient-centered.
Written by Dr. Rebecca Reyes, Psychiatrist and Clinical Advisor at Creyos
Dr. Rebecca Reyes is a psychiatrist and leader in behavioral healthcare with dual degrees in medicine and law. She has held leadership roles across inpatient and outpatient settings, directed military/PTSD and substance use treatment programs, and served as both principal and sub-investigator in several phase 3 neuropsychiatry clinical trials. She is committed to evidence-based care, collaborative leadership, and advancing patient outcomes across diverse healthcare environments.